Related Experiment Videos
Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis
S Sato1, M Fujimoto, M Hasegawa
1Department of Dermatology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan. s-sato@med.kanazawa-u.ac.jp
Rheumatology (Oxford, England)
|July 22, 2004
Summary
Soluble cytotoxic T-lymphocyte associated molecule-4 (sCTLA-4) is elevated in diffuse systemic sclerosis (SSc) and correlates with disease severity. sCTLA-4 may play a role in SSc immunological abnormalities.
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Background:
- Systemic sclerosis (SSc) is a complex autoimmune disease characterized by fibrosis.
- The role of immune dysregulation, including T-cell responses, in SSc pathogenesis is increasingly recognized.
- Soluble cytotoxic T-lymphocyte associated molecule-4 (sCTLA-4) is a marker involved in immune regulation.
Purpose of the Study:
- To investigate serum levels of sCTLA-4 in patients with systemic sclerosis (SSc).
- To determine the association between sCTLA-4 levels and clinical manifestations and disease activity in SSc.
- To explore the potential role of sCTLA-4 in the immunological abnormalities observed in SSc.
Main Methods:
- Serum sCTLA-4 levels were measured using enzyme-linked immunosorbent assay (ELISA) in patients with diffuse cutaneous SSc (dSSc) and limited cutaneous SSc (lSSc), as well as in healthy controls and patients with systemic lupus erythematosus (SLE).
- A longitudinal analysis of sCTLA-4 levels was performed in a subset of SSc patients over a follow-up period of 2.1-7.0 years.
- Clinical data, including disease duration, specific skin manifestations, pulmonary function, and autoantibody levels, were correlated with sCTLA-4 levels.
Main Results:
- Serum sCTLA-4 levels were significantly elevated in patients with dSSc compared to controls, lSSc patients, and SLE patients.
- Elevated sCTLA-4 levels in SSc patients were associated with shorter disease duration, digital pitting scars, contractures, diffuse pigmentation, pulmonary fibrosis, and reduced vital capacity (%VC).
- sCTLA-4 levels showed positive correlations with the extent of skin fibrosis, serum IgG levels, and anti-topoisomerase I antibody levels. Longitudinal data indicated a decrease in sCTLA-4 with improvement in skin sclerosis.
Conclusions:
- These findings suggest that sCTLA-4 is a potential biomarker for disease severity and activity in SSc.
- The elevated sCTLA-4 levels and their correlation with clinical parameters indicate its involvement in SSc pathogenesis.
- sCTLA-4 may contribute to immunological abnormalities in SSc by modulating T-cell and B-cell responses through interference with B7-CTLA-4 interactions.